Dimerix Ltd Market Cap ($89.21 Million)
Market Cap & Net Worth: Dimerix Ltd (DXB)
Dimerix Ltd market cap. Dimerix Ltd (AU:DXB) has a market capitalization of $89.21 Million (AU$126.08 Million) as of November 1, 2026. Listed on the AU stock exchange, this Australia-based company holds position #19448 globally and #623 in its home market, demonstrating a 2.44% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dimerix Ltd's stock price AU$0.21 by its total outstanding shares 600396776 (600.40 Million). Also see DXB cash flow conversion for how efficiently the company converts equity into cash flow.
Dimerix Ltd Market Cap History (2015–2026)
Dimerix Ltd market cap history from 2015 to 2026. Data shows growth from $55.65 Million to $89.21 Million (3.11% CAGR). Check Dimerix Ltd stock quote for real-time trading data and today's change.
Dimerix Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dimerix Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Dimerix Ltd equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
186.24x
Dimerix Ltd's market cap is 186.24 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $55.65 Million | $610.27K | -$5.25 Million | 91.19x | N/A |
| 2017 | $52.17 Million | $554.62K | -$1.76 Million | 94.06x | N/A |
| 2018 | $37.13 Million | $845.29K | -$3.32 Million | 43.92x | N/A |
| 2019 | $54.25 Million | $1.45 Million | -$2.89 Million | 37.49x | N/A |
| 2020 | $98.09 Million | $2.34 Million | -$4.49 Million | 41.90x | N/A |
| 2021 | $102.25 Million | $4.44 Million | -$6.37 Million | 23.03x | N/A |
| 2022 | $60.54 Million | $6.46 Million | -$10.49 Million | 9.37x | N/A |
| 2023 | $87.09 Million | $36.79K | -$13.80 Million | 2367.36x | N/A |
| 2024 | $144.44 Million | $583.48K | -$17.07 Million | 247.55x | N/A |
| 2025 | $233.65 Million | $1.25 Million | -$13.25 Million | 186.24x | N/A |
Competitor Companies of DXB by Market Capitalization
Companies near Dimerix Ltd in the global market cap rankings as of November 1, 2026. Also see balance sheet size of Dimerix Ltd for a full breakdown of the balance sheet.
Key companies related to Dimerix Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Dimerix Ltd (2015–2026)
Market capitalization of Dimerix Ltd from 2015 to today. Between 2015 and today, Dimerix Ltd's market cap moved from $55.65 Million to $ 89.21 Million, with a yearly change of 3.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$89.21 Million | -61.82% |
| 2025 | AU$233.65 Million | +61.76% |
| 2024 | AU$144.44 Million | +65.85% |
| 2023 | AU$87.09 Million | +43.86% |
| 2022 | AU$60.54 Million | -40.80% |
| 2021 | AU$102.25 Million | +4.24% |
| 2020 | AU$98.09 Million | +80.81% |
| 2019 | AU$54.25 Million | +46.11% |
| 2018 | AU$37.13 Million | -28.83% |
| 2017 | AU$52.17 Million | -6.26% |
| 2016 | AU$55.65 Million | 0.00% |
| 2015 | AU$55.65 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Dimerix Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $89.21 Million USD |
| MoneyControl | $89.21 Million USD |
| MarketWatch | $89.21 Million USD |
| marketcap.company | $89.21 Million USD |
| Reuters | $89.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Dimerix Ltd
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is… Read more